Sanofi and GlaxoSmithKline say their COVID-19 vaccine triggers a strong immune response, bolstering the late-comer program's potential as a booster shot
Sanofiand GlaxoSmithKlinesaid that their experimental COVID-19 vaccine succeeded in a mid-stage trial.
- The pharma giants plan to launch a pivotal-stage study with 35,000 volunteers in the coming weeks.
- The shot suffered from disappointing data and delays in 2020. The companies now hope for approval by year's end.
One of the world's most closely watched
Sanofi and GlaxoSmithKline, two of the largest vaccine-makers in the world, said in a press release that their experimental
Read more: GlaxoSmithKline stumbled with COVID-19 shots. Now it's facing an exodus of US talent and an uncertain future as the world's vaccine leader.
The companies did not release specific data on the antibody response, nor did they publish results in a peer-reviewed medical journal or post a paper on a preprint server.
Instead, the companies issued a press release describing the neutralizing antibody responses as "comparable to those generated by natural infection."
Neutralizing antibodies are the virus-fighting proteins that play a critical role in our immune response. GSK and Sanofi added that younger volunteers had generally stronger immune responses to the vaccine.
The two pharma giants expect to launch a final-stage clinical study, called a Phase 3 trial, in the coming weeks that will enroll more than 35,000 people. They also plan to simultaneously run smaller studies that test their vaccine, including versions tailored to neutralize specific coronavirus variants, as booster shots in people who've already been immunized.
If everything goes to plan, Sanofi and GSK expect their vaccine to be approved in October, November, or December of 2021, the companies said.
- Flyers are 'skiplagging' to try and save money on flight tickets. Airlines hate it.
- Electricity prices in Finland flipped negative — a huge oversupply of clean, hydroelectric power meant suppliers were almost giving it away
- After Germany enters recession, fears in Singapore of 'technical recession'
- Samsung Galaxy A34 5G review: A Mid-range marvel
- 10 ways to reduce your home loan EMI burden
- Global trends, macroeconomic data to drive equity markets this week: Analysts
- New Parliament building inauguration: 'Sarva-Dharma Prarthana' ceremony held
- List of Famous things to buy in Coorg